Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · IEX Real-Time Price · USD
1.960
-0.040 (-2.00%)
At close: May 20, 2024, 3:57 PM
1.990
+0.030 (1.53%)
After-hours: May 20, 2024, 7:55 PM EDT

Company Description

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia.

The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.

It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease.

The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019.

Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Limited
Alterity Therapeutics logo
Country Australia
Founded 1997
Industry Biotechnology
Sector Healthcare
Employees 11
CEO Dr. David A. Stamler M.D.

Contact Details

Address:
Level 3, 460 Bourke Street
Melbourne, C3 VIC 3000
Australia
Phone 61 3 9349 4906
Website alteritytherapeutics.com

Stock Details

Ticker Symbol ATHE
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001131343
CUSIP Number 02155X106
ISIN Number US02155X2053
SIC Code 2834

Key Executives

Name Position
Geoffrey Paul Kempler B.Sc. Co-Founder and Non-Executive Chairman
Dr. David A. Stamler M.D. Chief Executive Officer
Phillip Allen Hains BBus(Acc), C.A., M.B.A. Chief Financial Officer and Company Secretary
Dr. Rudolph Emile Tanzi Ph.D. Chief Scientific Advisor and Member of Research and Development Advisory Board
Dr. Steven D. Targum Chief Medical Advisor
Dr. Robert Cherny Head of Research

Latest SEC Filings

Date Type Title
May 9, 2024 6-K Report of foreign issuer
Apr 30, 2024 6-K Report of foreign issuer
Apr 29, 2024 6-K Report of foreign issuer
Apr 29, 2024 6-K Report of foreign issuer
Apr 17, 2024 6-K Report of foreign issuer
Apr 15, 2024 6-K Report of foreign issuer
Apr 12, 2024 6-K Report of foreign issuer
Apr 12, 2024 6-K Report of foreign issuer
Mar 26, 2024 6-K Report of foreign issuer
Mar 15, 2024 6-K Report of foreign issuer